1.Ayatollahi H, Gholamhosseini L, Salehi M: Predicting coronary artery disease: a comparison between two data mining algorithms. BMC Public Health 2019, 19(1):448.
2.Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA et al: HDL cholesterol efflux capacity and incident cardiovascular events. New Engl J Med 2014, 371(25):2383–2393.
3.Luo M, Liu A, Wang S, Wang T, Hu D, Wu S, Peng D: ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci Rep 2017, 7(1):2312.
4.Haraguchi Y, Toh R, Hasokawa M, Nakajima H, Honjo T, Otsui K, Mori K, Miyamoto-Sasaki M, Shinohara M, Nishimura K et al: Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis 2014, 234(2):288–294.
5.Ormseth MJ, Yancey PG, Yamamoto S, Oeser AM, Gebretsadik T, Shintani A, Linton MF, Fazio S, Davies SS, Roberts LJ, 2nd et al: Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. IJC Metab Endoc 2016, 13:6–11.
6.Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH: The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009, 50 Suppl:S189–194.
7.Norimatsu K, Kuwano T, Miura SI, Shimizu T, Shiga Y, Suematsu Y, Miyase Y, Adachi S, Nakamura A, Imaizumi S et al: Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease. Heart Vessels 2017, 32(1):30–38.
8.Patel PJ, Khera AV, Wilensky RL, Rader DJ: Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Failure 2013, 15(11):1215–1219.
9.Wu S, Chen X, Yuan S, Peng D, Zhou A, Li J: Impaired cholesterol efflux capacity is related to increased carotid intima media thickness in patients with end-stage renal disease. Int J Cardiol 2015, 187:456–458.
10.Liu C, Zhang Y, Ding D, Li X, Yang Y, Li Q, Zheng Y, Wang D, Ling W: Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study. Atherosclerosis 2016, 249:116–124.
11.Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA et al: Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscl, Thromb Vasc Biol 2013, 33(7):1696–1705.
12.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264–269, W264.
13.Agarwala AP, Rodrigues A, Risman M, McCoy M, Trindade K, Qu L, Cuchel M, Billheimer J, Rader DJ: High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arterioscl, Thromb Vasc Biol 2015, 35(6):1515–1519.
14.Asztalos BF, Horvath KV, Schaefer EJ: High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk. Arterioscl, Thromb Vasc Biol 2018, 38(9):2007–2015.
15.Attia N, Nakbi A, Smaoui M, Chaaba R, Moulin P, Hammami S, Hamda KB, Chanussot F, Hammami M: Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. Tohoku J Exp Med 2007, 213(2):129–137.
16.Ebtehaj S, Gruppen EG, Bakker SJL, Dullaart RPF, Tietge UJF: HDL (High-Density Lipoprotein) Cholesterol Efflux Capacity Is Associated With Incident Cardiovascular Disease in the General Population. Arterioscl, Thromb Vasc Biol 2019, 39(9):1874–1883.
17.Guerin M, Silvain J, Gall J, Darabi M, Berthet M, Frisdal E, Hauguel-Moreau M, Zeitouni M, Kerneis M, Lattuca B et al: Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol 2018, 72(25):3259–3269.
18.Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K: High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis 2015, 242(1):318–322.
19.Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL et al: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New Engl J Med 2011, 364(2):127–135.
20.Luo M, Zhang Z, Peng Y, Wang S, Peng D: The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity. Cardiovasc Dietol 2018, 17(1):142.
21.Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J et al: Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 2015, 3(7):507–513.
22.Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, Oda MN, Zhao XQ, Heinecke JW: Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 2014, 114(11):1733–1742.
23.Shea S, Stein JH, Jorgensen NW, McClelland RL, Tascau L, Shrager S, Heinecke JW, Yvan-Charvet L, Tall AR: Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. Arterioscl, Thromb Vasc Biol 2019, 39(1):89–96.
24.Wang G, Mathew AV, Yu H, Li L, He L, Gao W, Liu X, Guo Y, Byun J, Zhang J et al: Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease. PloS one 2018, 13(3):e0193782.
25.Zhang J, Xu J, Wang J, Wu C, Xu Y, Wang Y, Deng F, Wang Z, Chen X, Wu M et al: Prognostic Usefulness of Serum Cholesterol Efflux Capacity in Patients With Coronary Artery Disease. Am J Cardiol 2016, 117(4):508–514.
26.Kini AS, Vengrenyuk Y, Shameer K, Maehara A, Purushothaman M, Yoshimura T, Matsumura M, Aquino M, Haider N, Johnson KW et al: Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study. J Am Coll Cardiol 2017, 69(6):628–640.
27.Hafiane A, Jabor B, Ruel I, Ling J, Genest J: High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol 2014, 113(2):249–255.